Neck Surgeons Articles & Analysis: Older
18 news found
Perimeter Medical Imaging AI, Inc. (TSX-V: PINK)(OTC: PYNKF) (FSE: 4PC) (“Perimeter” or the “Company”) announced the publication of a peer-reviewed research article in JAMA Otolaryngology—Head and Neck Surgery. The study’s findings validate the further exploration of the use of Perimeter’s wide-field Optical Coherence Tomography (WF-OCT) technology to ...
Oral surgeons have the skillset and the technology to transform their patients’ mouths. ...
Jeremy Richmon, MD is leading a new clinical trial sponsored by Alume, the Center for Clinical Research Operations' (CCRO) first clinical trial with Head and Neck Surgery. The trial involves using a tracer to help identify nerves intraoperatively. This type of cutting edge translational surgical innovation improves outcomes and ultimately the lives of our patients. The amount of coordination and ...
Tissuemed Ltd. was recently able to support the 2nd African Head and Neck Society (AfHNS) Conference. The company’s TissuePatch surgical sealant film is a useful adjunct to ENT and Head and and Neck Surgery, often used to seal tissue surfaces and therefore minimise the need for postoperative drainage. ...
This Phase I-II study relates to the Investigational New Drug (IND) application for the use of ALM-488 in head and neck surgery. ALM-488 was developed by Alume Biosciences Inc. and is an intravenously administered peptide-dye conjugate for fluorescence highlighting of nerves during surgery. ...
Expansion of Pipeline Into a Third Neuronal Cell Type Builds on Existing Capabilities Intellectual Property Has Been Filed Covering Composition and Methods for Generating Auditory Neuronal Progenitors Hearing Loss Afflicts More Than 5% of the Population; More Than 430 Million People Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company ...
Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Helios Dr. Horst Schmidt Kliniken Wiesbaden in Germany was the first hospital outside the United States to offer the Company’s PROPEL® Contour (mometasone furoate) sinus implant following functional endoscopic ...
The American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS), in partnership with Intersect ENT, Inc., launched a public education campaign that provides clinically-developed information by experts in the field aimed at helping people better understand their nasal and sinus symptoms. ...
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues will host Chronic Rhinosinusitis (CRS) Key Opinion Leader Event on Tuesday, August 31, 2021 from 3:00 p.m. - 4:30 p.m. ET. Robert Kern, ...
There is a clear need for innovative tools and a broadened armamentarium that can help physicians treat patients suffering from CRS,” states Rajiv Pandit, MD, Otolaryngologist at Dallas ENT Head & Neck Surgery. “Balloon sinus dilation offers CRS patients a convenient, less-invasive, lower-cost solution by providing rapid resolution of symptoms with a minimal risk ...
Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced it has received CE Mark approval for the company’s PROPEL Contour (mometasone furoate) sinus implant enabling sales and distribution in the European Union. The Contour CE approval expands the portfolio of PROPEL products ...
Alume Biosciences, Inc., a clinical stage biotechnology company developing nerve-targeted pharmaceuticals for surgical and therapeutic use, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead compound ALM-488. ALM-488 is an investigational fluorescently labelled nerve targeting pharmaceutical being developed as an adjunct for the ...
A recently published small prospective series of patients with recurrent head and neck (H&N) cancers treated with surgical resection and Isoray’s Cesium-131 brachytherapy found potential benefits that support further research into combination therapy with Cesium-131 brachytherapy and surgical resection. The prospective series was conducted at the University Hospitals Cleveland Medical ...
Sisson Professor and Chair, Department of Otolaryngology – Head and Neck Surgery, Northwestern University Feinberg School of Medicine. Dr. ...
The Phase II SBIR grant is a follow-on 2–year award that will support testing of Alume's fluorescent nerve targeting agent in an ongoing Phase 1/2 clinical trial in patients undergoing Head and Neck Surgery. "Alume's technology was developed out of the unmet need to improve intraoperative identification of nerves to avoid inadvertent injury," said Quyen Nguyen, MD/PhD ...
Head and neck cancer surgery presents a number of unique challenges, not only for the surgeon but for the radiation oncologist who will subsequently treat those patients. ...
Sofregen Medical, Inc. (Sofregen), an early stage commercial biotechnology company developing products for medical aesthetics and reconstructive surgery, announced today that Silk Voice has been cleared by the U.S. Food and Drug Administration (FDA) for augmenting vocal fold tissue for phonation improvement. This is the first and only FDA cleared product made from solubilized silk protein and is ...
The American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting & OTO Expo will take place in Chicago, Illinois on September 10-13, 2017. It is an event that showcases the latest advances in the specialty and exposes surgeons to new research findings, approaches and treatment options to deliver excellent patient ...